Cardio Diagnostics Holdings, Inc. 2026: Revenue $5.36K, EPS ($0.51) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Cardio Diagnostics Holdings reported Q2 2026 results with $5.36K revenue and a net loss of $1.5M, or diluted EPS of ($0.51). Revenue declined 28.3% YoY, though the net loss narrowed by 10.8%. The company is in an early commercialization stage, shifting strategy toward non-reimbursement channels like telemedicine while securing CPT codes and initial commercial coverage. Operational updates include launching an in-house lab and initiating reagent shipments for India.
Cardio Diagnostics Holdings, Inc. reported results for the 2026 quarter, with nominal revenue of $5.36K and a net loss of ($1.5M), or diluted loss per share of ($0.51), reflecting ongoing commercialization and operating investment.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $5.36K | $7.48K | (28.3%) |
| Net income² | ($1.5M) | ($1.68M) | 10.8% |
| Diluted EPS³ | ($0.51) | ($0.97) | 47.4% |
¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per common share”.
Business Highlights
- Revenue remained nominal at $5.4K for the quarter ($8.0K year-to-date), reflecting the company's early commercialization stage.
- Go-to-market strategy shifted toward non-reimbursement channels including telemedicine, concierge/functional practices, employers, unions and benefit brokers.
- Reimbursement progress included secured CPT PLA codes, CMS gapfill rates at $854 per test and initiation of out-of-network commercial claims; the company secured its first commercial coverage with AHP.
- Operationally, the company brought up an in-house high-complexity CLIA lab and began testing (New York pending license) and started reagent shipments for an India rollout.
- Ongoing activities include clinical and economic studies, pursuing Medicare and broader commercial coverage, expanding product pipeline (stroke, heart failure, diabetes) and seeking partnerships.
Original SEC Filing: Cardio Diagnostics Holdings, Inc. [ CDIO ] - 10-Q - Aug. 07, 2026